NCT04243434 2020-04-16PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant PatientsAcrotech Biopharma Inc.Phase 1 Unknown56 enrolled
NCT01309789 2017-06-28A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell NeoplasmsSeagen Inc.Phase 1 Completed39 enrolled